Loading organizations...

§ Private Profile · Helsinki, Southern Finland, Finland
TILT Biotherapeutics is a technology company.
TILT Biotherapeutics is a clinical-stage biotechnology company developing next-generation immunotherapies for solid tumors. Its patented TILT® technology utilizes engineered oncolytic viruses, delivered intravenously, armed with immunostimulatory cytokines. These viruses replicate selectively in cancer cells, transforming "cold" tumors into immune-active sites by enhancing T-cell responses.
Founded in 2013 by oncologist Akseli Hemminki, M.D., Ph.D., TILT Biotherapeutics originated from his extensive research into oncolytic viruses. His work, including a compassionate treatment program, highlighted immunity’s critical role in viral cancer therapy. This insight into activating the immune system against tumors formed the company's foundation.
The company targets patients with solid tumors, especially those unresponsive to existing immunotherapies. TILT Biotherapeutics aims to advance cancer treatment through oncolytic viral technologies that activate the immune system. Its vision is a future where cancer patients access innovative, life-saving therapies, enhancing their longevity and quality of life.
TILT Biotherapeutics has raised $91.9M across 7 funding rounds.
TILT Biotherapeutics has raised $91.9M in total across 7 funding rounds.
TILT Biotherapeutics has raised $91.9M in total across 7 funding rounds.
TILT Biotherapeutics's investors include Lifeline Ventures, European Innovation Council, Stephen Industries, Tesi, Amadeus Capital Partners, Timo Ahopelto, ACME Investments SPF Sarl, Hermann Hauser, Miia Kaye, European Commission.
TILT Biotherapeutics has raised $91.9M across 7 funding rounds. Most recently, it raised $25.0M Series B in May 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2025 | $25M Series B | Lifeline Ventures, European Innovation Council, Stephen Industries, Tesi | Amadeus Capital Partners | Announced |
| Feb 7, 2023 | $23.6M Venture Round | Timo Ahopelto | Acme Investments SPF Sarl, Hermann Hauser, Stephen Industries | Announced |
| Feb 1, 2023 | $11M Series U | — | Amadeus Capital Partners, Lifeline Ventures | Announced |
| Jun 14, 2022 | $10.4M Venture Round | Timo Ahopelto | Miia Kaye | Announced |
| Jun 1, 2022 | $10M Series U | — | Amadeus Capital Partners, Lifeline Ventures | Announced |
| Jun 16, 2020 | $7.6M Debt Financing | — | — | Announced |
| Dec 14, 2016 | $4.3M Venture Round | — | European Commission, Timo Ahopelto | Announced |
TILT Biotherapeutics is a clinical‑stage biotechnology company developing engineered oncolytic adenovirus therapies designed to reshape the tumor microenvironment and enable potent T‑cell–based immunotherapies for solid tumors[2][1].
High‑Level Overview
For product/company specifics: TILT develops *TILT‑series* oncolytic adenoviruses (lead asset TILT‑123) armed with immune‑modulating cytokines to be used alone or in combination with T‑cell therapies (e.g., tumor‑infiltrating lymphocytes, checkpoint inhibitors, CAR‑T) to overcome local immunosuppression in solid tumors[1][2]. The therapies are intended for oncology researchers, clinicians, and ultimately patients with advanced solid cancers[1][2]. TILT‑123 is in Phase I clinical testing and has shown strong preclinical responses supporting clinical development[1].
Origin Story
Core Differentiators
Role in the Broader Tech/Healthcare Landscape
Quick Take & Future Outlook
If you’d like, I can: